DRUG RECALLS: OCTOBER 2011
OCTOBER 2011: Testosterone booster Uprizing 2:0 recalled due to undeclared drug ingredient called superdrol, a synthetic steroid making it an unapproved drug. Acute liver injury is known to be a possible harmful effect of using products containing synthetic anabolic steroids. Also may cause shrinkage of the testies and male infertility, masculilinzation of women, breast enlargement in males, short stature in children, heart attack, stroke, and death.
OCTOBER 2011: Sprycel (dasatinib) may increase the risk of a rare but serious condition in which there is abnormally high blood pressure in the arteries of the lungs. Symptoms may include shortness of breath, fatigue, swelling of the body such as the ankles and legs.
OCTOBER 2011: Nostrilla nasal decongestant recalled due to bacterial contamination. The bacteria is called Burkholderia cepacia that may cause serious infection in individuals with a compromised immune system or chronic lung condition.
OCTOBER 2011: Xigris [drotrecogin alfa (activated)] indicated for reduction in mortality in adult patients with severe sepsis who have a high risk of death was in market withdrawal due to Xigris failing to show a survival benefit for patients with severe sepsis and septic shock.
OCTOBER 2011: Birth control pills containing Drospirenone may have a possible increased risk of blood clots. This will be further reviewed and discussed.
